Astrazeneca plc

NASDAQ: AZN
$68.36
-$0.17 (-0.2%)
Closing price April 18, 2024
AstraZeneca is a global biopharmaceutical giant, dedicated to the discovery, development, and commercialization of prescription medicines. Its portfolio spans a wide range of areas including cardiovascular, renal, metabolism, oncology, and treatments for rare diseases and COVID-19. The company is known for leading products like Tagrisso, Imfinzi, and Lynparza, among others. AstraZeneca not only serves healthcare professionals and patients worldwide but also engages in significant collaborations, such as with Neurimmune AG, to push the boundaries of medicine. Headquartered in Cambridge, UK, AstraZeneca continues to be at the forefront of addressing global health challenges.
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Some investors are looking for conservative growth ideas, and big pharma may be the ticket. These four top stocks have been hit hard, and the companies have paid dependable dividends for years.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...
When companies see their shares rise by 100% or more in a single day, it's usually because of a buyout or an extremely positive change in a company's future prospects. For Genprex, it was a nod from...
AstraZeneca has announced that the FDA has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.
The top analyst upgrades, downgrades and initiations for Wednesday included Acorda Therapeutics, Activision Blizzard, Bloom Energy, Care.com, CBS, Deere and Ferrari.